SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluxion Biosciences announced today that it has expanded its sales and service network into Asia. The company signed a distribution agreement for its BioFlux™ line with Korea-based DI Biotech. A second agreement with Novel Science covers sales of both the BioFlux and IonFlux™ platforms in Japan. Fluxion has also sold its first BioFlux 1000 system into China. The China Academy of Chinese Medical Science will initially use this system for research on inhibition of thrombus formation on endothelial cells.
